With CMTA support of $206,000 over three years, the Inherited Neuropathy Consortium (INC) is maintaining and expanding the infrastructure needed to evaluate new therapies for all forms of CMT, including types that have not yet been genetically identified. This funding, which began in September 2022, supports 20 clinical sites, has led to the publication of more than 20 scientific papers, and enabled completion of the first large-scale natural history studies of CMT1B and CMTX1 (aka CMT1X, CMTX). With over 7,000 patients now enrolled in INC studies, and CMTX1 as the second-largest patient group, this unmatched data resource will support every future CMT clinical trial and Investigational New Drug (IND) application.
Building the Largest CMT Patient Data Set
Principal Investigator
Michael E. Shy, MD
Therapy / Approach
Natural History
Project Duration
3 Years
Total CMTA-STAR Project Investment
$206,000
